Literature DB >> 8817335

Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant.

R Sherrington1, S Froelich, S Sorbi, D Campion, H Chi, E A Rogaeva, G Levesque, E I Rogaev, C Lin, Y Liang, M Ikeda, L Mar, A Brice, Y Agid, M E Percy, F Clerget-Darpoux, S Piacentini, G Marcon, B Nacmias, L Amaducci, T Frebourg, L Lannfelt, J M Rommens, P H St George-Hyslop.   

Abstract

Missense mutations in the presenilin 2 (PS-2) gene on chromosome 1 were sought by direct nucleotide sequence analysis of the open reading frame of 60 pedigrees with familial Alzheimer's disease (FAD). In the majority of these pedigrees, PS-1 and beta-amyloid precursor protein (beta APP) gene mutations had been excluded. While no additional PS-2 pathogenic mutations were detected, four silent nucleotide substitutions and alternative splicing of nucleotides 1338-1340 (Glu325) were observed. Analysis of additional members of a pedigree known to segregate a Met239Val mutation in PS-2 revealed that the age of onset of symptoms is highly variable (range 45-88 years). This variability is not attributable to differences in ApoE genotypes. These results suggest (i) that, in contrast to mutations in PS-1, mutations in PS-2 are a relatively rare cause of FAD; (ii) that other genetic or environmental factor modify the AD phenotype associated with PS-2 mutations; and (iii) that still other FAD susceptibility genes remain to be identified.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8817335     DOI: 10.1093/hmg/5.7.985

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  76 in total

Review 1.  Presenilins: structural aspects and posttranslational events.

Authors:  F Checler
Journal:  Mol Neurobiol       Date:  1999-06       Impact factor: 5.590

Review 2.  Mouse models of Alzheimer's disease.

Authors:  Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2011-11-28       Impact factor: 4.077

Review 3.  Vaccines for Alzheimer's disease: how close are we?

Authors:  Christopher Janus
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 4.  New approaches to genetic counseling and testing for Alzheimer's disease and frontotemporal degeneration.

Authors:  Jill S Goldman
Journal:  Curr Neurol Neurosci Rep       Date:  2012-10       Impact factor: 5.081

5.  High prevalence of pathogenic mutations in patients with early-onset dementia detected by sequence analyses of four different genes.

Authors:  U Finckh; T Müller-Thomsen; U Mann; C Eggers; J Marksteiner; W Meins; G Binetti; A Alberici; C Hock; R M Nitsch; A Gal
Journal:  Am J Hum Genet       Date:  2000-01       Impact factor: 11.025

6.  Neuropsychological function in nondemented carriers of presenilin-1 mutations.

Authors:  J M Ringman; C Diaz-Olavarrieta; Y Rodriguez; M Chavez; L Fairbanks; F Paz; A Varpetian; H C Maldonado; M A Macias-Islas; J Murrell; B Ghetti; C Kawas
Journal:  Neurology       Date:  2005-08-23       Impact factor: 9.910

Review 7.  Mechanisms of neural and behavioral dysfunction in Alzheimer's disease.

Authors:  Daniel W Wesson; Ralph A Nixon; Efrat Levy; Donald A Wilson
Journal:  Mol Neurobiol       Date:  2011-03-22       Impact factor: 5.590

Review 8.  The solved and unsolved mysteries of the genetics of early-onset Alzheimer's disease.

Authors:  Ekaterina Rogaeva
Journal:  Neuromolecular Med       Date:  2002       Impact factor: 3.843

Review 9.  Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development.

Authors:  Joanna L Jankowsky; Alena Savonenko; Gabriele Schilling; Jiou Wang; Guilian Xu; David R Borchelt
Journal:  Curr Neurol Neurosci Rep       Date:  2002-09       Impact factor: 5.081

Review 10.  Epidemiology of Alzheimer disease.

Authors:  Richard Mayeux; Yaakov Stern
Journal:  Cold Spring Harb Perspect Med       Date:  2012-08-01       Impact factor: 6.915

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.